Neovasc Inc. with ticker code (NVCN) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 2.25 and 1.5 with a mean TP of 1.88. Given that the stocks previous close was at 0.87 this indicates there is a potential upside of 116.1%. The 50 day MA is 0.82 and the 200 day MA is 1.93. The market cap for the company is $24m. Company Website: http://www.neovasc.com
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.